Detalhe da pesquisa
1.
Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials.
J Hepatol
; 64(1): 19-28, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26321288
2.
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial.
Lancet
; 385(9973): 1075-86, 2015 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-25467591
3.
Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.
Gastroenterology
; 148(2): 355-366.e1, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25311593
4.
Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study.
Gut
; 64(6): 948-56, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25080450